GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
BeOne's degrader BG-60366 appears to have been discontinued.
Daraxonrasib scores a plenary session late-breaker.
The disclosure comes as another of Arcus's TIGIT trials flops.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
First-in-human results prompt a biomarker-defined approach for CID-078.
